Dudediligence.

Damora Therapeutics, Inc

DMRANASDAQ · Pharmaceutical Preparations
Write an idea

Fundamentals

Oldest to newest
Net income, by quarter
−$3.9MSep ’24−$6.7MDec ’24−$2.5MMar ’25−$3.4MJun ’25−$3.1MSep ’25−$200.7MDec ’25−$27.8MMar ’26−$31.2MJun ’26
Fiscal years, by the month each ended
LineDec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating income−$52.2M−$61.2M−$39.9M−$22.3M−$210.9M
Net income−$51.8M−$61.6M−$38.3M−$21.4M−$209.8M
Operating cash flow−$52.3M−$42.9M−$36.9M−$18.6M−$6.7M
Free cash flow−$52.5M−$43.1Mnone on filenone on filenone on file
Cash$62.6M$32.8M$21.5M$14.2M$257.6M
Shares outstanding25.3M25.7M1.1M1.3M1.6M